Regulatory AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer BioSpaceDecnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer.HematologyRead full story pharminent May 28, 2026 (Last updated: May 28, 2026) BioSpace Decnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer. Hematology Read full story Post navigation Previous: November date set for FDA decision on Sanofi’s Gaucher drugNext: GSK hails ‘unprecedented’ cure rates with hep B drug Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
